SGLT2 Inhibitors and Aging: A Promising Approach to Healthy Longevity

This review gathered evidence about SGLT2 inhibitors, medicines that make the kidneys remove extra sugar through urine. It examined human studies, along with research in animals and cells, on diabetes, heart disease, kidney disease, and aging-related processes. In people with type 2 diabetes, heart failure, or kidney disease, these medicines can lower the risk of some heart and kidney problems. Animal and cell findings suggest they might also affect aging, but the human studies were not designed to show longer life or slower aging.

What this means for you: People who already need these medicines may benefit when a clinician prescribes them, but this review does not show that healthy people should take them for longevity. Do not buy or start them for anti-aging purposes without medical advice.